Proton Pump Inhibitor Use Is Associated With an Increased Frequency of Hospitalization in Patients With Cystic Fibrosis

Background Proton pump inhibitors (PPIs) are among the most commonly prescribed medications in clinical practice. PPI use has been associated with the development of community-acquired pneumonia. With a reported prevalence of gastroesophageal reflux disease (GERD) and PPI use that is higher than the general population, patients with cystic fibrosis (CF) are particularly vulnerable to PPI adverse effects. We sought to explore whether PPI use was associated with a higher number of hospitalizations for CF pulmonary exacerbation. Methods We conducted a longitudinal retrospective review in an academic outpatient setting. Patients > 18 years of age with a diagnosis of CF and at least 1 year of follow-up were eligible for inclusion. Baseline characteristics, PPI use, and details of hospitalization through 1 year of follow-up were collected. Results One hundred fourteen patients met inclusion criteria. Fifty-nine patients (51.7%) were hospitalized at least once in the follow-up year, mean number of hospitalizations was 2.17 (± 1.9). At least 6 months of PPI use was observed in 59 patients (51.7%). In univariate analysis, PPI use was associated with a significantly higher mean number of hospitalizations (0.9 vs. 1.4, P = 0.009). In a multi-variable regression model, PPI use remained significantly associated with a higher number of hospitalizations (P = 0.03), while controlling for risk factors traditionally associated with increased pulmonary exacerbations. Conclusion PPI use is highly prevalent in CF patients. Exposure to PPI therapy is independently associated with a higher number of hospitalizations for pulmonary exacerbation in CF patients.

[1]  L. Hoffman,et al.  Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations , 2017, Pediatrics.

[2]  R. Sadikot.  Exacerbations of Cystic Fibrosis , 2016 .

[3]  J. Lam,et al.  Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis , 2015, PloS one.

[4]  E. DiMango,et al.  Prevalence of gastroesophageal reflux in cystic fibrosis and implications for lung disease. , 2014, Annals of the American Thoracic Society.

[5]  A. Munck,et al.  194 A French survey on gastro-oesophageal reflux in CF: need for guidance , 2014 .

[6]  D. Levy,et al.  Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis , 2014, BMC Pulmonary Medicine.

[7]  G. Verleden,et al.  The effect of gastric juice on interleukin-8 production by cystic fibrosis primary bronchial epithelial cells. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[8]  R. Smego,et al.  Four-Year Trends of Inappropriate Proton Pump Inhibitor Use After Hospital Discharge , 2013, Southern medical journal.

[9]  S. Baker,et al.  Evolution of pancreatic function during the first year in infants with cystic fibrosis. , 2013, The Journal of pediatrics.

[10]  P. Siersema,et al.  Proton pump inhibitor therapy predisposes to community‐acquired Streptococcus pneumoniae pneumonia , 2012, Alimentary pharmacology & therapeutics.

[11]  G. Sawicki,et al.  The impact of reflux burden on Pseudomonas positivity in children with Cystic Fibrosis , 2012, Pediatric pulmonology.

[12]  N. Gulati,et al.  Inappropriate Use of Intravenous PPI for Stress Ulcer Prophylaxis in an Inner City Community Hospital , 2010, Journal of clinical medicine research.

[13]  J. Inadomi,et al.  Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. , 2010, The American journal of managed care.

[14]  M. Ireland,et al.  Characteristics of gastroesophageal reflux in adults with cystic fibrosis. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[15]  Margaret Rosenfeld,et al.  Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. , 2010, American journal of respiratory and critical care medicine.

[16]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[17]  G. Verleden,et al.  Gastro-oesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis , 2008, Gut.

[18]  J. Hallas,et al.  Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. , 2007, Archives of internal medicine.

[19]  C. Goss,et al.  Exacerbations in cystic fibrosis · 1: Epidemiology and pathogenesis , 2007, Thorax.

[20]  F. Manguso,et al.  Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children , 2006, Pediatrics.

[21]  G. Mattioli,et al.  IL-8 and airway neutrophilia in children with gastroesophageal reflux and asthma-like symptoms. , 2006, Respiratory medicine.

[22]  G. Snell,et al.  Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  A. Oliver,et al.  Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[24]  Miriam C J M Sturkenboom,et al.  Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. , 2004, JAMA.

[25]  R. Valuck,et al.  A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. , 2004, Journal of clinical epidemiology.

[26]  T. Liou,et al.  Predictive 5-year survivorship model of cystic fibrosis. , 2001, American journal of epidemiology.

[27]  M. Walshaw,et al.  Tracheal Microaspiration in Adult Cystic Fibrosis , 1998, Journal of the Royal Society of Medicine.

[28]  L. Tibbling,et al.  Gastro-oesophageal reflux and severity of pulmonary disease in cystic fibrosis. , 1991, Scandinavian journal of gastroenterology.

[29]  M. Corey,et al.  The association of cystic fibrosis, gastroesophageal reflux, and reduced pulmonary function. , 1988, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[30]  T. Marrie,et al.  Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. , 2010, The American journal of medicine.

[31]  R. Hornung,et al.  Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. , 2002, Chest.

[32]  B. Strandvik,et al.  Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. , 2001, The European respiratory journal.